Gillian M Keating

Summary

Publications

  1. Scott L. Lixisenatide: a review of its use in patients with type 2 diabetes mellitus. BioDrugs. 2013;27:509-23 pubmed publisher
  2. Scott L. Enzalutamide: A Review in Castration-Resistant Prostate Cancer. Drugs. 2018;: pubmed publisher
  3. Frampton J. Brexpiprazole: A Review in Schizophrenia. Drugs. 2019;79:189-200 pubmed publisher
    ..Clinical evidence to date suggests it usefully extends the range of therapeutic options for schizophrenia. ..
  4. Kim E, Scott L. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. Target Oncol. 2017;12:373-383 pubmed publisher
    ..In conclusion, oral palbociclib combination therapy is a valuable emerging option for use in patients with HR-positive, HER2-negative advanced or metastatic breast cancer. ..
  5. Paik J, Deeks E. Tofacitinib: A Review in Psoriatic Arthritis. Drugs. 2019;79:655-663 pubmed publisher
  6. Deeks E. Ivermectin: A Review in Rosacea. Am J Clin Dermatol. 2015;16:447-52 pubmed publisher
    ..Thus, ivermectin 1% cream is an effective and well tolerated option for the topical treatment of inflammatory lesions of rosacea, with the convenience of once-daily application. ..
  7. Greig S, McKeage K. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease. CNS Drugs. 2016;30:79-90 pubmed publisher
    ..Thus, carbidopa/levodopa ER is an effective and generally well-tolerated treatment option for the motor symptoms of PD, reducing periods of 'off-time' compared with carbidopa/levodopa IR without increasing troublesome dyskinesia. ..
  8. Scott L. Fentanyl Iontophoretic Transdermal System: A Review in Acute Postoperative Pain. Clin Drug Investig. 2016;36:321-30 pubmed publisher
    ..Hence, fentanyl ITS is a useful option for the management of acute postoperative pain in adults requiring opioid analgesia in the hospital setting. ..
  9. McCafferty E, Dhillon S, Deeks E. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia. Paediatr Drugs. 2018;20:593-600 pubmed publisher
    ..Although long-term outcomes remain to be determined, dasatinib expands the first- and second-line options available for the treatment of Ph+ CML-CP in pediatric patients. ..

More Information

Publications386 found, 100 shown here

  1. Syed Y, Deeks E. [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment. CNS Drugs. 2015;29:605-13 pubmed publisher
    ..In summary, [(18)F]florbetaben is a highly accurate β-amyloid PET tracer that has the potential to support the clinical diagnosis of Alzheimer's disease and other causes of cognitive decline. ..
  2. Deeks E. Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2018;35:163-173 pubmed publisher
  3. Hoy S. Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. CNS Drugs. 2018;32:473-484 pubmed publisher
    ..Thus, lacosamide is a useful option for the management of focal-onset seizures across a broad age range, starting as early as 4 years of age. ..
  4. Dhillon S. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU. Clin Drug Investig. 2019;39:221-229 pubmed publisher
    ..Thus, current evidence indicates that neratinib provides a valuable option to reduce the risk of recurrence in this setting and has been included in the updated ESMO patient guide as an extended adjuvant therapy for some patients. ..
  5. Hoy S. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar. BioDrugs. 2019;33:117-120 pubmed publisher
    ..The role of reference pegfilgrastim in the management of chemotherapy-induced neutropenia is well established and pegfilgrastim-jmdb provides an effective biosimilar alternative for patients requiring pegfilgrastim therapy. ..
  6. Keating G. Sugammadex: A Review of Neuromuscular Blockade Reversal. Drugs. 2016;76:1041-52 pubmed publisher
    ..Intravenous sugammadex was generally well tolerated. In conclusion, sugammadex is an important option for the rapid reversal of rocuronium- or vecuronium-induced neuromuscular blockade. ..
  7. request reprint
    Keating G. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Target Oncol. 2016;11:825-835 pubmed
  8. Plosker G. Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. Drugs. 2015;75:887-97 pubmed publisher
    ..The most common adverse events were headache, diarrhoea and dizziness. ..
  9. Frampton J. Perampanel: A Review in Drug-Resistant Epilepsy. Drugs. 2015;75:1657-68 pubmed publisher
  10. Al Salama Z. PF-06438179/GP1111: An Infliximab Biosimilar. BioDrugs. 2018;32:639-642 pubmed publisher
    ..The role of reference infliximab in the management of autoimmune inflammatory conditions is well established and GP1111 provides an effective biosimilar alternative for patients requiring infliximab therapy. ..
  11. Shirley M, McCormack P. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs. 2014;74:579-86 pubmed publisher
    ..Thus, radium-223 is a valuable addition to the treatment options for this poor-prognosis population. ..
  12. Shirley M, Scott L. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76:1135-45 pubmed publisher
  13. Keating G. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253 pubmed publisher
    ..In conclusion, sorafenib remains an important option for the treatment of HCC. ..
  14. Deeks E. Cladribine Tablets: A Review in Relapsing MS. CNS Drugs. 2018;32:785-796 pubmed publisher
  15. Plosker G. Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs. 2015;75:1255-68 pubmed publisher
    ..Thus, the use of acamprosate as an adjunct to psychosocial interventions in alcohol-dependent patients provides modest but potentially valuable improvements in alcohol-consumption outcomes and is generally well tolerated. ..
  16. request reprint
    Keating G. Macitentan: A Review in Pulmonary Arterial Hypertension. Am J Cardiovasc Drugs. 2016;16:453-460 pubmed
    ..Macitentan was generally well tolerated in SERAPHIN. In conclusion, macitentan is an important option for the treatment of PAH. ..
  17. Deeks E. Mirabegron: A Review in Overactive Bladder Syndrome. Drugs. 2018;78:833-844 pubmed publisher
  18. Keating G. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014;74:1947-60 pubmed publisher
    ..In conclusion, intravenous clevidipine is a valuable agent for the management of BP in perioperative and intensive care settings. ..
  19. Syed Y. Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster. Drugs Aging. 2018;35:1031-1040 pubmed publisher
    ..RZV is not contraindicated in immunocompromised individuals, and is preferred over a live attenuated HZ vaccine in immunocompetent individuals, according to the US and Canadian guidelines. ..
  20. Al Salama Z, Scott L. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2018;19:907-918 pubmed publisher
    ..Guselkumab, administered by subcutaneous injection, is a useful new option for patients with moderate to severe plaque psoriasis. ..
  21. Carter N. Bilastine: in allergic rhinitis and urticaria. Drugs. 2012;72:1257-69 pubmed publisher
    ..e. cetirizine, levocetirizine and desloratadine). Bilastine was generally well tolerated, with a tolerability profile that was generally similar to that of the other second-generation antihistamines included in phase III clinical trials. ..
  22. Plosker G. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297-308 pubmed publisher
    ..Appropriate monitoring and dosage titration are important to achieve optimal clinical benefits of ruxolitinib. Further research, including studies evaluating ruxolitinib-based combination therapy, may also help to optimise treatment. ..
  23. Deeks E. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75:665-73 pubmed publisher
    ..However, further longer-term and active comparator-controlled studies would be beneficial, including trials powered to assess COPD exacerbations. ..
  24. Heo Y. GP2017: An Adalimumab Biosimilar. BioDrugs. 2018;: pubmed publisher
    ..The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy. ..
  25. McCormack P. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015;75:525-31 pubmed publisher
    ..Eltrombopag was generally well tolerated, with increased liver transaminases as the only dose-limiting toxicity. Clonal cytogenetic abnormalities were observed in 19 % of patients and dysplasia in 5 % of patients. ..
  26. Kim E, Deeks E. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. Drugs. 2015;75:1547-57 pubmed publisher
    ..As the first SGLT2 inhibitor/DPP-4 inhibitor fixed-dose combination available, empagliflozin/linagliptin is a useful new option for patients with T2D. ..
  27. Blair H. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. Drugs. 2018;78:1903-1910 pubmed publisher
    ..Therefore, daunorubicin/cytarabine liposome is an important treatment option for adults with newly diagnosed tAML or AML-MRC. ..
  28. Scott L. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections. Drugs. 2012;72:2141-65 pubmed publisher
  29. request reprint
    Dhillon S. Hydrocodone Bitartrate ER (Hysingla® ER): A Review in Chronic Pain. Clin Drug Investig. 2016;36:969-980 pubmed
  30. Heo Y, Scott L. Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. CNS Drugs. 2018;32:875-882 pubmed publisher
  31. Lamb Y. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs. 2018;: pubmed publisher
    ..g. lymphocytopenia, anaemia, thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone extends the treatment options available for the management of relapsed and/or refractory multiple myeloma. ..
  32. Shirley M. Dinoprostone Vaginal Insert: A Review in Cervical Ripening. Drugs. 2018;78:1615-1624 pubmed publisher
  33. Keating G. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74:1891-1925 pubmed publisher
    ..In conclusion, bevacizumab remains an important option for use in patients with advanced cancer. ..
  34. Burness C. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014;74:1961-1971 pubmed publisher
    ..Eltrombopag provides a new treatment option for thrombocytopenia in patients with chronic HCV infection to allow for optimal antiviral therapy. ..
  35. Keating G. Aflibercept: A Review of Its Use in Diabetic Macular Oedema. Drugs. 2015;75:1153-60 pubmed publisher
    ..Intravitreal aflibercept was generally well tolerated in patients with diabetic macular oedema. In conclusion, intravitreal aflibercept is an important new treatment for diabetic macular oedema. ..
  36. McCormack P. Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation. BioDrugs. 2015;29:207-14 pubmed publisher
    ..Overall survival data were not mature at the time of assessment. The improved efficacy with VR-CAP was accompanied by an increased incidence of grade 3 or higher adverse events, particularly haematological adverse events. ..
  37. Scott L. Peramivir: A Review in Uncomplicated Influenza. Drugs. 2018;78:1363-1370 pubmed publisher
  38. Heo Y, Dhillon S. Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy. Target Oncol. 2018;13:801-808 pubmed publisher
  39. Scott L. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia. Drugs. 2016;76:255-62 pubmed publisher
    ..Thus, subcutaneous asfotase alfa is a valuable emerging therapy for the treatment of bone manifestations in patients with paediatric-onset HPP. ..
  40. Paik J. PF-05280014: A Trastuzumab Biosimilar. BioDrugs. 2018;32:515-518 pubmed publisher
    ..The role of reference trastuzumab in the management of HER2-positive breast and gastric cancers is well established and PF-05280014 provides an effective biosimilar alternative for patients requiring trastuzumab therapy. ..
  41. Keating G. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27:479-89 pubmed publisher
    ..In conclusion, inhaled loxapine provides a novel new option for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia, combining a rapid onset of effect with a noninvasive route of administration. ..
  42. Frampton J. Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events. Drugs. 2015;75:797-808 pubmed publisher
    ..Based on these results, vorapaxar has been approved in the EU as an adjunctive treatment for the secondary prevention of atherothrombotic events in patients with prior MI who do not have a history of stroke, TIA or ICH. ..
  43. Shirley M, Dhillon S. Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures. Drugs. 2016;76:707-17 pubmed publisher
    ..The recent licensing of the drug in the USA as monotherapy expands the range of treatment options for patients with partial-onset seizures and increases the opportunity to tailor therapy to the individual patient. ..
  44. Lamb Y, Dhillon S. Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol Diagn Ther. 2017;21:225-232 pubmed publisher
    ..Nevertheless, currently available data suggests that Epi proColon® 2.0 CE has the potential to be a sensitive and convenient screening option for patients refusing screening by colonoscopy. ..
  45. Frampton J. Empagliflozin: A Review in Type 2 Diabetes. Drugs. 2018;78:1037-1048 pubmed publisher
    ..Given its demonstrable cardioprotective benefits, the drug is worthy of preferential consideration in patients at high CV risk who require an (additional) antidiabetic medication in order to attain their glycaemic goal. ..
  46. Greig S, Scott L, Plosker G. Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2014;14:463-70 pubmed publisher
    ..Therefore, epoprostenol AS is a valuable therapeutic option that has the potential to overcome some of the limitations of long-term intravenous epoprostenol therapy in patients with PAH. ..
  47. Keating G. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension. Drugs. 2015;75:197-206 pubmed publisher
    ..More data are needed to confirm the longer-term efficacy of droxidopa. Droxidopa was generally well tolerated, although patients should be monitored for supine hypertension. ..
  48. Dhillon S. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology. Target Oncol. 2015;10:303-10 pubmed publisher
    ..To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ..
  49. Dhillon S. Regorafenib: A Review in Metastatic Colorectal Cancer. Drugs. 2018;78:1133-1144 pubmed publisher
  50. Deeks E. Highly Purified Human Menopausal Gonadotropin (Menopur®): A Profile of Its Use in Infertility. Clin Drug Investig. 2018;38:1077-1084 pubmed publisher
    ..Moreover, compared with rFSH, Menopur® appeared to be associated with a less pronounced follicular response and a lower risk of ovarian overstimulation. ..
  51. Blair H. Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. Drugs. 2018;78:1741-1750 pubmed publisher
  52. Greig S, Keating G. Naltrexone ER/Bupropion ER: A Review in Obesity Management. Drugs. 2015;75:1269-80 pubmed publisher
  53. Keating G. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease. Drugs. 2017;77:201-208 pubmed publisher
    ..Lifitegrast ophthalmic solution 5% was generally well tolerated. In conclusion, lifitegrast ophthalmic solution 5% provides a new option for the treatment of dry eye disease. ..
  54. Dhillon S. Eculizumab: A Review in Generalized Myasthenia Gravis. Drugs. 2018;78:367-376 pubmed publisher
    ..Although several questions remain, such as duration of treatment, cost effectiveness and long-term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gMG. ..
  55. Blair H. Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain. Drugs. 2018;78:1489-1500 pubmed publisher
    ..In conclusion, the capsaicin 8% dermal patch is a useful addition to the treatment options currently available for patients with PNP. ..
  56. Blair H, Deeks E. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75:61-74 pubmed publisher
    ..Thus, inhaled umeclidinium/vilanterol extends the treatment options currently available for the maintenance treatment of adults with COPD and has the convenience of once-daily administration. ..
  57. Deeks E. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs. 2015;75:1027-38 pubmed publisher
    ..Thus, ombitasvir/paritaprevir/ritonavir plus dasabuvir is an effective interferon-free, direct-acting antiviral regimen for use ± ribavirin in a broad range of adults chronically infected with HCV genotype 1. ..
  58. Scott L. Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs. 2018;78:479-493 pubmed publisher
    ..Thus, ferric carboxymaltose remains an important option for the treatment of ID in adults and, where approved, children aged ≥ 14 years, when oral iron preparations are ineffective or cannot be used. ..
  59. Heo Y, Deeks E. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. Drugs. 2018;78:577-587 pubmed publisher
  60. Plosker G. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73:959-77 pubmed publisher
  61. Blair H, Keating G. Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75:651-63 pubmed publisher
    ..Thus, albiglutide is an effective and generally well tolerated treatment option for patients with inadequately controlled type 2 diabetes. ..
  62. Shirley M, Dhillon S. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years. BioDrugs. 2015;29:353-61 pubmed publisher
    ..Although some questions remain, including the duration of the protective response, rLP2086 vaccine has the potential to be a valuable tool for the prevention of invasive MenB disease. ..
  63. Al Salama Z, Garnock Jones K, Scott L. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma. Target Oncol. 2017;12:535-542 pubmed publisher
  64. Syed Y. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT. Drugs. 2017;77:1473-1480 pubmed publisher
    ..Therefore, lenalidomide offers a valuable maintenance treatment option for this population. ..
  65. Hoy S. Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia. Drugs. 2018;78:1605-1613 pubmed publisher
    ..Moreover, the incidence of hypokalemia was low. Current evidence indicates that SZC is a promising therapy for the management of hyperkalaemia in adults. ..
  66. McCormack P. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. Drugs Aging. 2015;32:409-18 pubmed publisher
    ..In conclusion, continuous lenalidomide regimens provide an effective longer-term treatment option in patients with newly diagnosed multiple myeloma ineligible for stem-cell transplantation. ..
  67. Keating G. Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs. 2015;75:1425-34 pubmed publisher
    ..In conclusion, intravenous cangrelor is an important new option for use in patients undergoing PCI who have not been treated with oral P2Y12 inhibitors. ..
  68. Hoy S. Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma. Target Oncol. 2016;11:255-62 pubmed publisher
  69. Garnock Jones K. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. BioDrugs. 2015;29:57-67 pubmed publisher
    ..Vedolizumab is a useful addition to the treatment options available for patients with moderately to severely active ulcerative colitis and Crohn's disease. ..
  70. Scott L. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS Drugs. 2013;27:971-88 pubmed publisher
    ..Therefore, glatiramer acetate remains a valuable first-line option in the treatment of RRMS and is an option for delaying the onset of CDMS in patients with CIS. ..
  71. McCormack P. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs. 2014;74:1693-9 pubmed publisher
    ..Thus, omalizumab is an effective and well-tolerated add-on therapy in patients with chronic spontaneous urticaria who are symptomatic despite background therapy with H1 antihistamines. ..
  72. McKeage K. Linagliptin: an update of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:1927-1946 pubmed publisher
    ..Meanwhile, the low risk of hypoglycaemia and the nonrenal route of elimination may provide important advantages for some patient groups, including elderly or renally impaired patients. ..
  73. Greig S, Plosker G. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. Drugs. 2015;75:533-42 pubmed publisher
  74. McKeage K. Ruxolitinib: A Review in Polycythaemia Vera. Drugs. 2015;75:1773-81 pubmed publisher
    ..Thus, for a subgroup of PV patients for whom few treatment options have existed previously, ruxolitinib provides a valid option. ..
  75. Garnock Jones K. Prucalopride: A Review in Chronic Idiopathic Constipation. Drugs. 2016;76:99-110 pubmed publisher
    ..No cardiovascular safety issues have arisen with prucalopride treatment. Although further long-term and comparative data would be beneficial, prucalopride provides an additional treatment option for patients with CIC. ..
  76. McKeage K. Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older. Paediatr Drugs. 2016;18:75-81 pubmed publisher
  77. Al Salama Z, Keating G, Keam S. Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events. Drugs. 2017;77:2025-2036 pubmed publisher
  78. Hoy S. Nusinersen: A Review in 5q Spinal Muscular Atrophy. CNS Drugs. 2018;: pubmed publisher
  79. Dhillon S. ABP 980: A Trastuzumab Biosimilar. BioDrugs. 2018;32:511-514 pubmed publisher
  80. Deeks E. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018;78:1817-1828 pubmed publisher
  81. Dhillon S. Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease. Drugs. 2015;75:1405-12 pubmed publisher
  82. Garnock Jones K. Brexpiprazole: A Review in Schizophrenia. CNS Drugs. 2016;30:335-42 pubmed publisher
    ..Overall, oral brexpiprazole is a useful treatment option for the treatment of patients with schizophrenia. ..
  83. Dhillon S, Pace D. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review. Drugs. 2017;77:1881-1896 pubmed publisher
  84. Syed Y. Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs. 2018;32:883-890 pubmed publisher
    ..It offers a convenient once every 6 months treatment regimen, with no need for routine monitoring. ..
  85. Scott L. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs. 2014;74:2153-60 pubmed publisher
    ..This article reviews the pharmacology and therapeutic efficacy of rifaximin 550 mg twice daily in reducing the recurrence of overt HE episodes in adults with liver disease. ..
  86. Hoy S. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2015;29:171-9 pubmed publisher
  87. Kim E, Keating G. Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism. Drugs. 2015;75:1293-303 pubmed publisher
  88. Greig S, Keating G. Ramucirumab: A Review in Advanced Gastric Cancer. BioDrugs. 2015;29:341-51 pubmed publisher
  89. Keating G. Axitinib: a review in advanced renal cell carcinoma. Drugs. 2015;75:1903-13 pubmed publisher
    ..In conclusion, axitinib is an important option in previously-treated patients with advanced RCC. ..
  90. Scott L. Lacosamide: A Review in Focal Seizures in Patients with Epilepsy. Drugs. 2015;75:2143-54 pubmed publisher
  91. Hoy S. Dinutuximab: A Review in High-Risk Neuroblastoma. Target Oncol. 2016;11:247-53 pubmed publisher
  92. Heo Y, Duggan S. Niraparib: A Review in Ovarian Cancer. Target Oncol. 2018;13:533-539 pubmed publisher